^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19 inhibitor

    Related drugs:
    1d
    Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. (clinicaltrials.gov)
    P1, N=60, Recruiting, Janux Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    2d
    Efficacy and Safety of Inebilizumab in the Treatment of Relapsing Neuromyelitis Optica Spectrum Disorder : A Multicenter, Randomized Controlled, Open-Label Study (ChiCTR2600119728)
    P4, N=80, Completed, Affiliated Provincial Hospital of Shandong First Medical University (Shandong Provincial Hospital); Affiliated Provincial Hospital of Shandong First M
    New P4 trial
    |
    Uplizna (inebilizumab-cdon)
    3d
    Safety of blinatumomab combined with dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (PubMed, Zhongguo Dang Dai Er Ke Za Zhi)
    Blinatumomab combined with dasatinib is well tolerated in pediatric Ph+ ALL, and the adverse events are manageable.
    Retrospective data • Journal
    |
    ABL1 (ABL proto-oncogene 1)
    |
    dasatinib • Blincyto (blinatumomab)
    3d
    AAAV0505: A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=6, Suspended, Columbia University | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • NKX019
    4d
    A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=26, Not yet recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P2 --> P1/2 | Initiation date: Mar 2026 --> Jun 2026
    Phase classification • Trial initiation date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    6d
    CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular Therapy. (PubMed, Blood Cancer Discov)
    In this phase II study, TAK-007, an off-the-shelf allogeneic CD19 CAR NK-cell therapy expressing IL-15, demonstrates encouraging response rates, rapid treatment availability, and an excellent safety profile in heavily pretreated B-cell lymphoma, including post-CAR-T patients, albeit with limited durability. These findings, supported by integrated translational analyses, provide important mechanistic insights into CAR-NK biology that may guide future optimization and bring this approach closer to broader clinical application. See related article by Darrah et al., p. XX .
    Journal
    |
    IL15 (Interleukin 15)
    |
    TAK-007
    9d
    Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Feb 2026 --> Sep 2026
    Trial initiation date
    11d
    KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, TCRx Therapeutics Co.Ltd | N=30 --> 18 | Initiation date: May 2025 --> Sep 2025 | Trial primary completion date: Jun 2028 --> Dec 2028
    Enrollment change • Trial initiation date • Trial primary completion date
    |
    CD19 positive
    11d
    Single Ascending Dose Study of HB2198 in Healthy Participants (clinicaltrials.gov)
    P1, N=32, Recruiting, Hinge Bio | Not yet recruiting --> Recruiting
    Enrollment open
    11d
    Soundtrack-E: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=408, Recruiting, AstraZeneca | N=276 --> 408 | Trial completion date: Feb 2028 --> Jun 2029
    Enrollment change • Trial completion date
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisone • surovatamig (AZD0486)
    15d
    A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) (clinicaltrials.gov)
    P1/2, N=200, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    16d
    Challenges of Hepatitis B Virus Reactivation and CD19 Testing Following Tafasitamab Plus Lenalidomide for Relapsed Diffuse Large B-Cell Lymphoma. (PubMed, J Med Cases)
    CD19 expression may be diminished by exams using a tafasitamab-competitive-binding clone. This case highlights not only the concern of HBV reactivation, but also the diagnostic challenge due to CD19 epitope masking following tafasitamab therapy.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    lenalidomide • Monjuvi (tafasitamab-cxix)